title: Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
abstract: OBJECTIVE
  Leukemia-derived dendritic cells (DC(leu)) potentially present the whole leukemic antigen repertoire. We studied antigen-expression profiles of blasts/dendritic cells (DCs) generated from 137 acute myeloid leukemia (AML)/49 myelodysplastic syndromes (MDS) patients with six different DC-generating media by flow-cytometry combining expression of blast/maturation and DC antigens (DCA:CD1a,b,c, CD25, CD40, CD80, CD83, CD86, CD137-L and CD206).
  
  
  RESULTS
  First, DCA are regularly and variably expressed on uncultured blasts/mononuclear cells (MNCs). Individual patients' DCA profiles must be evaluated before DC-culture to find suitable DCA to estimate quality/quantity of DC after culture. Second, after culture in every patient, at least one marker fulfilled these criteria. Third, different DC-generating methods showed varying efficiency to generate DC: not every method was always successful. Fourth, individual FACS-DCA profiles showed a successful DC/DC(leu) generation with at least one of three previously tested methods in every given AML/MDS case. Fifth, pooling results of all selected best methods in every given case, 28/30% DC were generated from AML/MDS samples: >60% viable DC, on average 49/56% mature DC and on average 36% of blasts were convertible to DC(leu) resulting in on average 49% DC(leu) of AML-DC.
  
  
  CONCLUSIONS
  Individual DCA-expression profiles should be evaluated before culture to evaluate DC counts/subtypes (mature/viableDC, DC(leu)) in individual patients.
authors.affiliation: Medical Department III, University Hospital Großhadern, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Dreyssig
authors.forename: Andreas
authors.initials: A
authors.lastname: Kremser
authors.forename: Anja
authors.initials: A
authors.lastname: Liepert
authors.forename: Christine
authors.initials: C
authors.lastname: Grabrucker
authors.forename: Markus
authors.initials: M
authors.lastname: Freudenreich
authors.forename: Christoph
authors.initials: C
authors.lastname: Schmid
authors.forename: Tanja
authors.initials: T
authors.lastname: Kroell
authors.forename: Nina
authors.initials: N
authors.lastname: Scholl
authors.forename: Johanna
authors.initials: J
authors.lastname: Tischer
authors.forename: Stephany
authors.initials: S
authors.lastname: Kufner
authors.forename: Helmut
authors.initials: H
authors.lastname: Salih
authors.forename: Hans-Jochem
authors.initials: HJ
authors.lastname: Kolb
authors.forename: Helga Maria
authors.initials: HM
authors.lastname: Schmetzer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000941:Antigens / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D037181:Lectins, C-Type / Q000032:analysis; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation; D008297:Male; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins / Q000032:analysis; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000276:immunology* / Q000628:therapy; D011956:Receptors, Cell Surface / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000941:Antigens; D037181:Lectins, C-Type; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D011956:Receptors, Cell Surface